Published Paper Details:

Gastrointestinal disorders impose a substantial global health burden, characterized by disruptions in gut function and imbalances in the gut microbiome. Probiotics have emerged as promising bioagents for managing these disorders through modulating the gut microbiota. This comprehensive review thoroughly explores the role of probiotics in mitigating gastrointestinal disorders, emphasizing efficacy, safety, and future potentials. Amidst treatment challenges posed by chronic inflammatory conditions like ulcerative colitis and Crohn's disease, probiotics offer prospective solutions by influencing immune responses, preserving intestinal barrier integrity, and impeding tumor development. Clinical investigations validate probiotics' effectiveness in treating infectious and antibiotic-associated diarrhea in adults, alongside allergic disorders in children. Furthermore, bacteriocins derived from probiotics showcase efficacy in gastrointestinal ailment management. Nevertheless, uncertainties linger in probiotics' application for managing inflammatory bowel diseases (IBD), attributed to incongruous outcomes in experimental and clinical realms. This review critically assesses the current probiotics landscape, underscoring safety considerations and advocating for optimized formulations for enhanced outcomes. A profound comprehension of probiotic mechanisms stands pivotal for steering future research and therapeutic breakthroughs. Despite challenges, probiotics hold promise in alleviating the global burden of gastrointestinal maladies, necessitating persistent research to surmount obstacles and ensure their judicious, secure, and efficacious application.